KIN-003 is a small molecule commercialized by Kinnate Biopharma, with a leading Phase I program in Bile Duct Cancer (Cholangiocarcinoma). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of KIN-003’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for KIN-003 is expected to reach an annual total of $8 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

KIN-003 Overview

KIN-3248 is under development for the treatment of FGFR2-fusion positive intrahepatic cholangiocarcinoma (ICC) and FGFR3-altered urothelial carcinoma. The drug candidates acts by targeting FGFR2 and 3. It is administered through oral route.

Kinnate Biopharma Overview

Kinnate Biopharma is a biotechnology company that focuses on the discovery and development of small molecule kinase inhibitor candidates for difficult-to-treat, cancers associated with genetic alterations. It is advancing the development of its lead-targeted therapy FGFR and RAF candidates. The company harnesses the proprietary, unique co-crystal structure of KIN002787 in the BRAF protein and biomarker-driven approach to drive the preclinical and clinical development of its translational research programs. Kinnate Biopharma also carries out small molecule development programs, such as Cyclin-Dependent Kinase 12 (CDK12) inhibitor. It has operations in San Francisco, the US. Kinnate Biopharma is headquartered in San Diego, California, the US.

The operating loss of the company was US$90.1 million in FY2021, compared to an operating loss of US$36 million in FY2020. The net loss of the company was US$89.8 million in FY2021, compared to a net loss of US$35.8 million in FY2020.

For a complete picture of KIN-003’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.